Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Donafenib Combined With Immunotherapy and Local Therapy for Unresectable Hepatocellular Carcinoma That Has Failed in Previous Therapy

NCT06496815 is registered in ClinicalTrials.gov with Tongji Hospital as lead sponsor.

NCT NCT06496815
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06496815 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Donafenib Combined With Immunotherapy and Local Therapy for Unresectable Hepatocellular Carcinoma That Has Failed in Previous Therapy
Lead sponsor
Tongji Hospital
Phase
Phase 4
Overall status
Not yet recruiting
Start date
August 1, 2024
Completion date
July 30, 2027
Enrollment
32 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

unresectable hepatocellular carcinoma